SITC Presidential Session Discussion

Patrick Hwu, MD
Head, Division of Cancer Medicine

Professor and Chairman Departments of
Melanoma and Sarcoma Medical Oncology
Co-Director Center for Cancer Immunology Research

The University of Texas MD Anderson Cancer Center

SITC

Washington, DC
November 10, 2018

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

Disclosures

Scientific Advisory Board:

Immatics US, Inc.
Dragonfly
Sanofi

GlaxoSmithKline

Cancers are Driven by Mutations or Copy Number Alterations

SKCM = Skin Cutaneous Melanoma

LUSC = Lung Squamous Cell Carcinoma

LUAD = Lung Adenocarcinoma

BLCA = Bladder Urothelial Carcinoma

DLBCL = Diffuse Large B-cell Lymphoma

STAD = Stomach Adenocarcinoma

CHOL = Cholangiocarcinoma

ESCA = Esophageal Carcinoma

HNSC = Head and Neck Squamous Cell Carcinoma

CESC = Cervical Squamous Cell Carcinoma

LIHC = Liver Hepatocellular Carcinoma



Courtesy of Alexander Lazar (MDACC), Juliann Shih (Broad), Andrew Cherniack (Broad) & Sarcoma TCGA AW

Many low mutation cancers do not respond to current immunotherapies

ACC = Adenoid Cystic Carcinoma
BRCA = Breast Cancer
COAD = Colon Adenocarcinoma
DDLPS = Dedifferentiated Liposarcoma
GBA = Glioblastoma Brain Tumor
KICH = Kidney Renal Clear Cell Carcinoma
KIRC = Kidney Renal Papillary Cell Carcinoma
LAML = Acute Myeloid Leukemia
LGG = Lower Grade Glioma
MFS = Myxofibrosarcoma
MPNST = Malignant Peripheral Nerve Sheath Tumors
OV = Ovarian Cancer
PCPG = Pheochromocytoma and Paraganglioma
PAAD = Pancreatic Adenocarcinoma
PRAD = Prostate Adenocarcinoma
READ = Rectum Adenocarcinoma
SS = Sjogrens Syndrome
STMLS = Soft Tissue Leiomyosarcoma
TGCT = Testicular Germ Cell Tumor
THCA = Thyroid Carcinoma
THYM = Thymoma
UCEC = Uterine Corpus Endometrial Carcinoma
UCS = Uterine Carcinoma
ULMS = Uterine Leiomyosarcoma
UPS = Undifferentiated Pleomorphic Sarcoma
UVM = Uveal Melanoma



Courtesy of Alexander Lazar (MDACC), Juliann Shih (Broad), Andrew Cherniack (Broad) & Sarcoma TCGA AWG.

Insertion of Genes into Lymphocytes to Enhance Antitumor Properties





Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors

Dr. Kristin Anderson
Post-doctoral Research Fellow
Philip D. Greenberg Lab
November 10th, 2018
kganders@fredhutch.org or ande8527@uw.edu

FRED HUTCH™
CURES START HERE

UNIVERSITY of WASHINGTON

Engineered Fas Immunomodulatory Fusion Proteins may overcome induced T cell death and promote cell proliferation/survival



Shannon Oda, PhD

SITC 2018 NOVEMBER 7–11 • WASHINGTON, D.C.

Endoplasmic reticulum stress-induced transcription factor C/EBP homologous protein (Chop) thwarts effector T cell activity in tumors through repression of T-bet

Yu Cao Ph.D.

Department of Immunology

H. Lee Moffitt Cancer Center & Research Institute

sitc

Society for Immunotherapy of Cancer

#SITC2018

6. Chop deletion increases the effect of T-cell-based immunotherapy







Insertion of Genes into Lymphocytes to Enhance Antitumor Properties